Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine- Resistant Chronic Hepatitis B
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination therapy in patients with LAM-resistant chronic hepatitis B. Methods: Seventy-five patients who received LAM-ADV combination therapy for more than 12 months were analyzed. Restriction fragment mass polymorphism assays were used to detect and monitor the dynamics of LAM- and ADVresistant mutations. Results: The median duration of LAMADV combination therapy was 26 months (range, 12 to 58 months). The baseline mutation profiles, rtM204I (p=0.992), rtM204I/V (p=0.177), and rtL180M (p=0.051), were not correlated with the cumulative virological response, and the baseline HBV DNA level (p=0.032) was the only independent predictive factor for cumulative virological response. Tests for LAM- and ADV-resistant mutations were performed in 12 suboptimal responders in weeks 48 and 96. The population of rtM204 mutants persisted or increased in 8 of 12 patients, and rtA181T mutants newly emerged as a minor population in four patients until 96 weeks. Nevertheless, the viral loads progressively decreased during rescue therapy, and these dynamics did not correlate with virological response. Conclusions: The baseline profile and dynamics of LAM-resistant mutations during LAM-ADV combination therapy are not associated with a virological response.
Abstract
Background/Aims: To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination therapy in patients with LAM-resistant chronic hepatitis B. Methods: Seventy-five patients who received LAM-ADV combination therapy for more than 12 months were analyzed. Restriction fragment mass polymorphism assays were used to detect and monitor the dynamics of LAM- and ADVresistant mutations. Results: The median duration of LAMADV combination therapy was 26 months (range, 12 to 58 months). The baseline mutation profiles, rtM204I (p=0.992), rtM204I/V (p=0.177), and rtL180M (p=0.051), were not correlated with the cumulative virological response, and the baseline HBV DNA level (p=0.032) was the only independent predictive factor for cumulative virological response. Tests for LAM- and ADV-resistant mutations were performed in 12 suboptimal responders in weeks 48 and 96. The population of rtM204 mutants persisted or increased in 8 of 12 patients, and rtA181T mutants newly emerged as a minor population in four patients until 96 weeks. Nevertheless, the viral loads progressively decreased during rescue therapy, and these dynamics did not correlate with virological response. Conclusions: The baseline profile and dynamics of LAM-resistant mutations during LAM-ADV combination therapy are not associated with a virological response.
참고문헌 (29)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- Lai CL, "Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B", Clin Infect Dis, 36, pp.687~696 (2003)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
- Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B", Hepatology, d45, pp.307~313 (2007)
- Gaia S, "Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine", J Hepatol, 48, pp.540~547 (2008)
- Yatsuji H, "Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year followup", J Hepatol, 48, pp.923~931 (2008)
- Hosaka T, "Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine", J Gastroenterol, 42, pp.368~374 (2007)
- Kurashige N, "Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B", J Gastroenterol, 44, pp.601~607 (2009)
- Suzuki F, "Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy", J Med Virol, 78, pp.1025~1034 (2006)
- Kim HJ, "The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment", Liver Int, 32, pp.303~310 (2012)
- Aizawa M, "Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients", J Med Virol, 83, pp.953~961 (2011)
- Wu S, "Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B", Dig Dis Sci, 56, pp.1207~1214 (2011)
- Inoue J, "Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern", J Viral Hepat, 18, pp.206~215 (2011)
- van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
- Liaw YF, "The development of cirrhosis in patients with chronic type B hepatitis: a prospective study", Hepatology, 8, pp.493~496 (1988)
- Hong SP, "Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments", J Hepatol, 40, pp.837~844 (2004)
- Kim HJ, "Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy", J Gastroenterol Hepatol, 25, pp.1374~1380 (2010)
- Zoulim F, "Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection", Antiviral Res, 64, pp.1~15 (2004)
- Ijaz S, "Dynamics of lamivudineresistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy", J Med Virol, 80, pp.1160~1170 (2008)
- Ono SK, "The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance", J Clin Invest, 107, pp.449~455 (2001)
- Moriconi F, "Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment", J Antimicrob Chemother, 60, pp.341~349 (2007)
- Yim HJ, "Hepatitis B virus genetic diversity and mutant", Korean J Hepatol, 14, pp.446~464 (2008)
- Lee CH, "Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough", Gastroenterology, 130, pp.1144~1152 (2006)
- Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
- Lee SH, "Pre-existing YMDD mutants in treatment-naive patients with chronic hepatitis B are not selected during lamivudine therapy", J Med Virol, 84, pp.217~222 (2012)